Serum Levels of Soluble CD26, A Novel Prognostic Marker for Hepatitis E Infection

Background: Even without treatment, most acute hepatitis E virus (HEV) infected patients resolve HEV but sometimes the disease leads to acute liver failure, chronic infection, or extrahepatic symptoms. The mechanisms of HEV pathogenesis appear to be substantially immune mediated. However, the immune responses to HEV are not precisely identified. Objectives: This study aimed to evaluate the Th1/Th2 ratio by investigating serum soluble markers from Th1 and Th2 cells in acute HEV infected patients. Patients and Methods: This case-control study included 35 acute HEV infected patients and 35 age and gender matched anti-HEV negative healthy controls. The serum levels of Interferon (IFN)-gamma, IL-4, soluble CD26 (5CD26) and sCD30 were determined by the enzyme-linked immunosorbent assay. Results: The results showed a significant difference in LEN-gamma and 5CD26 (P < 0.0001 and P = 0.001) yet not IL-9 and sCD30 (P = 0354 and P = 0.159) between acute HEV patients and controls, respectively. There was a positive direct correlation between serum levels of sCD26 and IFN-gamma in acute HEV patients (r = 0.64, P= 0.001). In addition, the ratio of sCD26/sCDN in the acute HEV group was more than two folds higher than in the HEV negative controls. Conclusions: Acute HEV infection shows a pattern of Thl-type immune response, and the direct significant positive correlation between the serum level of sCD26 and IEN-y in acute HEV infected patients, suggests that the trend of sCD26 levels is a valuable marker for predicting hepatic inflammation in hepatitis E.